Further, we identified ARSA as a NAFLD/NASH-induced hepatokine that regulates hepatic and systemic lysophospholipid metabolism, and as powerful modulator of skeletal muscle insulin action. Here, ARSA is linked to metabolic dysfunction-associated steatohepatitis.